Your browser doesn't support javascript.
loading
Novel ester tethered dihydroartemisinin-3-(oxime/thiosemicarbazide)isatin hybrids as potential anti-breast cancer agents: Synthesis, in vitro cytotoxicity and structure-activity relationship.
Liu, Shaohuan; Wang, Shu; Xu, Dan; Pan, Bowen; Chen, Linzhi; Zhao, Shijia; Xu, Zhi; Zhou, Wei.
Afiliação
  • Liu S; West China School of Pharmacy, Sichuan University, Chengdu, Sichuan Province, China.
  • Wang S; School of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
  • Xu D; West China School of Pharmacy, Sichuan University, Chengdu, Sichuan Province, China.
  • Pan B; School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou, People's Republic of China.
  • Chen L; School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou, People's Republic of China.
  • Zhao S; School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou, People's Republic of China.
  • Xu Z; School of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
  • Zhou W; School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou, People's Republic of China.
Drug Dev Res ; 84(6): 1175-1182, 2023 09.
Article em En | MEDLINE | ID: mdl-37165798
ABSTRACT
A series of ester tethered dihydroartemisinin-3-(oxime/thiosemicarbazide)isatin hybrids 7a-p were designed, synthesized, and assessed for their antiproliferative activity against MCF-7, MDA-MB-231, MCF-7/ADR, and MDA-MB-231/ADR breast cancer cell lines. Among them, hybrids 7a,f (IC50 1.33-3.84 µM) showed potent activity against triple-negative (MDA-MB-231 and MDA-MB-231/ADR) breast cancer cell lines, and hybrid 7f (IC50 3.90 and 10.18 µM) also demonstrated promising activity against estrogen receptor-positive breast cancer cells (MCF-7 and MCF-7/ADR), and the activity was superior to these of artemisinin, dihydroartemisinin, and ADR, revealing their potential to fight against both drug-sensitive and drug-resistant breast cancers. The enriched structure-activity relationships may facilitate further design of more active candidates.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Isatina / Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Isatina / Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article